
Results
7
Companies which are more than 50% undervalued based on analyst price target.
7 companies
Caliway Biopharmaceuticals
Market Cap: NT$169.5b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$113.50
7D
9.1%
1Y
-40.3%
Lotus Pharmaceutical
Market Cap: NT$51.9b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$196.00
7D
8.6%
1Y
1.0%
Oneness Biotech
Market Cap: NT$23.2b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
4743
NT$48.30
7D
0.7%
1Y
-30.4%
TaiMed Biologics
Market Cap: NT$17.4b
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
4147
NT$63.70
7D
-2.3%
1Y
-18.8%
Medigen Vaccine Biologics
Market Cap: NT$17.4b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$52.90
7D
1.3%
1Y
35.3%
EirGenix
Market Cap: NT$15.6b
Operates as a contract development and manufacturing company in Taiwan and internationally.
6589
NT$51.20
7D
-0.6%
1Y
-16.9%
Foresee Pharmaceuticals
Market Cap: NT$12.6b
Operates as biopharmaceutical company in the United States, China, and Europe.
6576
NT$79.80
7D
-1.0%
1Y
-2.6%